Cargando…
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260563/ https://www.ncbi.nlm.nih.gov/pubmed/30477533 http://dx.doi.org/10.1186/s12967-018-1704-3 |
_version_ | 1783374821447434240 |
---|---|
author | Pu, Xingxiang Zhang, Ran Wang, Li Chen, Yungchang Xu, Yi Pataer, Apar Meraz, Ismail M. Zhang, Xiaoshan Wu, Shuhong Wu, Lin Su, Dan Mao, Weimin Heymach, John V. Roth, Jack A. Swisher, Stephen G. Fang, Bingliang |
author_facet | Pu, Xingxiang Zhang, Ran Wang, Li Chen, Yungchang Xu, Yi Pataer, Apar Meraz, Ismail M. Zhang, Xiaoshan Wu, Shuhong Wu, Lin Su, Dan Mao, Weimin Heymach, John V. Roth, Jack A. Swisher, Stephen G. Fang, Bingliang |
author_sort | Pu, Xingxiang |
collection | PubMed |
description | BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media containing human interleukin-2 and characterized the proliferated lymphocytes by flow cytometric assays with antibodies specific for human immune cell surface markers. Presence of immune cells in PDXs was also determined by immunohistochemical staining. RESULTS: Human tumor-infiltrating lymphocytes (TILs) were cultured from nine of 25 PDX samples (36%). The mean time of PDX growth in immunodeficient mice before obtaining TILs in culture was 113 days (range 63–292 days). The TILs detected in PDXs were predominantly human CD8(+) T cells, CD4(+) T cells, or CD19(+) B cells, depending on cases. DNA fingerprint analysis showed that the TILs originated from the same patients as the PDXs. Further analysis of two PDX-derived CD8(+) T cells showed that they were PD-1(−), CD45RO(+), and either CD62L(+) or CD62L(−), suggesting they were likely memory T cells. Immunohistochemical staining showed that human T cells (CD8(+) or CD4(+)), B cells (CD19(+)), and macrophages (CD68(+)) were present in stroma or intraepithelial cancer structures and that human PD-L1 was expressed in stromal cells. Moreover, the patient-derived immune cells in PDX can be passaged to the F2 generation and may migrate to spleens of PDX-bearing mice. CONCLUSIONS: Patient-derived immune cells co-exist in early passages of PDXs in some lung cancer PDX models. The CD8(+) cells from PDXs were likely memory T cells. These results suggest that PDXs can be used for evaluating the functionality of immune components in tumor microenvironments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1704-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6260563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62605632018-11-30 Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer Pu, Xingxiang Zhang, Ran Wang, Li Chen, Yungchang Xu, Yi Pataer, Apar Meraz, Ismail M. Zhang, Xiaoshan Wu, Shuhong Wu, Lin Su, Dan Mao, Weimin Heymach, John V. Roth, Jack A. Swisher, Stephen G. Fang, Bingliang J Transl Med Research BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media containing human interleukin-2 and characterized the proliferated lymphocytes by flow cytometric assays with antibodies specific for human immune cell surface markers. Presence of immune cells in PDXs was also determined by immunohistochemical staining. RESULTS: Human tumor-infiltrating lymphocytes (TILs) were cultured from nine of 25 PDX samples (36%). The mean time of PDX growth in immunodeficient mice before obtaining TILs in culture was 113 days (range 63–292 days). The TILs detected in PDXs were predominantly human CD8(+) T cells, CD4(+) T cells, or CD19(+) B cells, depending on cases. DNA fingerprint analysis showed that the TILs originated from the same patients as the PDXs. Further analysis of two PDX-derived CD8(+) T cells showed that they were PD-1(−), CD45RO(+), and either CD62L(+) or CD62L(−), suggesting they were likely memory T cells. Immunohistochemical staining showed that human T cells (CD8(+) or CD4(+)), B cells (CD19(+)), and macrophages (CD68(+)) were present in stroma or intraepithelial cancer structures and that human PD-L1 was expressed in stromal cells. Moreover, the patient-derived immune cells in PDX can be passaged to the F2 generation and may migrate to spleens of PDX-bearing mice. CONCLUSIONS: Patient-derived immune cells co-exist in early passages of PDXs in some lung cancer PDX models. The CD8(+) cells from PDXs were likely memory T cells. These results suggest that PDXs can be used for evaluating the functionality of immune components in tumor microenvironments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1704-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-26 /pmc/articles/PMC6260563/ /pubmed/30477533 http://dx.doi.org/10.1186/s12967-018-1704-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Pu, Xingxiang Zhang, Ran Wang, Li Chen, Yungchang Xu, Yi Pataer, Apar Meraz, Ismail M. Zhang, Xiaoshan Wu, Shuhong Wu, Lin Su, Dan Mao, Weimin Heymach, John V. Roth, Jack A. Swisher, Stephen G. Fang, Bingliang Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title_full | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title_fullStr | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title_full_unstemmed | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title_short | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
title_sort | patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260563/ https://www.ncbi.nlm.nih.gov/pubmed/30477533 http://dx.doi.org/10.1186/s12967-018-1704-3 |
work_keys_str_mv | AT puxingxiang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT zhangran patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT wangli patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT chenyungchang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT xuyi patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT pataerapar patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT merazismailm patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT zhangxiaoshan patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT wushuhong patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT wulin patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT sudan patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT maoweimin patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT heymachjohnv patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT rothjacka patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT swisherstepheng patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer AT fangbingliang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer |